Home Alzheimer’s Disease Saad Z. Usmani, on the Approval of Daratumumab and Hyaluronidase-fihj

Saad Z. Usmani, on the Approval of Daratumumab and Hyaluronidase-fihj

In an interview with CancerNetwork®, Saad Z. Usmani, MD, FACP, hematologist and medical oncologist at Levine Cancer Institute, spoke about the recent approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma. 

The addition of this product now allows for subcutaneous dosing of daratumumab.

“One of the concerns that medical oncologists have had is the long infusion time [of daratumumab], especially in the first cycle of treatment,” said Usmani. “The subcutaneous formulation of daratumumab brings a lot of convenience to the patients.” 

The combination of daratumumab and hyaluronidase-fihj is now approved for the following indications, of which intravenous daratumumab had already received approval:

  • In combination with bortezomib (Velcade), melphalan (Evomela), and prednisone (Rayos)…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments